UCB.BRUCB.BR
ImmunologyNeurology80 cited findings · profile updated 2026-08-25
224.10 EURnot live — refreshed daily
About UCB.BR
UCB.BR is engaged in the development of therapies across immunology and neurology. In immunology, Cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as for adults with moderately to severely active rheumatoid arthritis and active psoriatic arthritis. Bimzelx has been evaluated for its safety profile, with Grade 4 decreases in neutrophils observed in 2 (0.1)% of cases and Grade 3 decreases in neutrophils in 14 (0.8)% of cases. In neurology, Fintepla has been studied in trials with patient enrollment ranging from 14 to 158 patients across various centers in the US, Canada, Europe, Australia, and Japan. Brivaracetam, another neurological agent, showed a neutrophil count Grade 3 of 5.7% and a decrease in neutrophils meeting NCI Grade 2 criteria in 47.2% of cases.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Grade 4 decreases in neutrophils | 2 (0.1) % | UCB S A — Bimzelx EMA EPAR public assessment report (EMEA/H/C/005316,, p.211 |
| Grade 3 decreases in neutrophils | 14 (0.8) % | UCB S A — Bimzelx EMA EPAR public assessment report (EMEA/H/C/005316,, p.211 |
| IGA 0 or 1 with ≥2 grade improvement (%) | 31 % | UCB INC — Cimzia FDA Review (NDA/BLA 125160, 2021), p.83 |
| Neutrophil reduction Grade 4 (BKZ 320mg Q4W) | 0.6 % | UCB S A — Bimzelx EMA EPAR public assessment report (EMEA/H/C/005316,, p.182 |
| neutrophil count Grade 3 | 5.7 % | UCB SA — Briviact (in Italy: Nubriveo) EMA EPAR public assessment repo, p.102 |
| decrease in neutrophils meeting NCI Grade 2 criteria | 47.2 % | UCB SA — Briviact (in Italy: Nubriveo) EMA EPAR public assessment repo, p.102 |
Key projects
- CIMZIA (treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy)
CIMZIA received a new indication approval for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- CIMZIA (treatment of adult patients with active psoriatic arthritis)
CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis.
- CIMZIA (treatment of adults with moderately to severely active rheumatoid arthritis)
CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis.
- Bimzelx — EU
Bimzelx had an application submission date of 15 July 2020 in the EU.
- Rystiggo — EU
Rystiggo received orphan medicinal product designation on 22 April 2020 in the EU.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →